reSULTS
In Slovakia, there are no exact data on the incidence and prevalence of COPD, and so information can only be based on available data on the number of patients who are registered under the outpatient ICD code J44 (International Classification of Diseases (ICD). According to data from NHIC (National Health Information Center), in 2010 there were 91,023 patients with COPD being followed (Table 1) (11) .
MeTHODS
The survey was performed by Delphi panel to obtain information on the management of patients with COPD and to estimate the direct costs of disease management. The survey included 4 experts experienced in COPD treatment. The studied population were cohorts of COPD patients (mild form of COPD, moderate form, severe form and very severe form). COPD stages are classified according to GOLD guidelines 2014. GOLD COPD classifications are used to describe the severity of the obstruction or airflow limitation: mild form (FEV1/FVC*<0.70; FEV1≥ 80% normal); moderate form (FEV1/FVC<0.70; FEV1 50-79% normal), severe form (FEV1/FVC<0.70; FEV1 30-49% normal) and very severe form (FEV1/FVC<0.70; FEV1 <30% normal, or <50% normal with chronic respiratory failure present) (5,6,7). The costs were set for one average patient per 3 months of treatment. The cost data were assessed and updated as of 1 st November 2013. All types of healthcare used in COPD management were evaluated (hospitalization, outpatient visits, diagnostics, laboratory tests and the management of symptoms, use of bronchodilators). The mild form and severe form of exacerbation were also evaluated and the costs were set for one single event/exacerbation. The analysis was performed from the Slovakian health insurance perspective reflecting direct medical costs only. The structure of cost data follows the requirements of pharmacoeconomic modelling in COPD.
The resources were evaluated based on the following source of data:
• Drug costs: list of reimbursed drugs valid from November 2013 (8).
• Hospitalisation costs: data from the Central Registry of Contracts (9).
• Procedures costs: data from the Central Registry of Contracts (9) and Catalogue of medical procedures (10).
For drugs administered during outpatient visits, administration costs were applied. Hospitalization costs were applied for drugs administered during an inpatient stay.
Exacerbation of COPD is an event in the course of the disease that manifests as a worsening of dyspnea, cough and expectoration of sputum (14). Patients with mild exacerbations and good lung function are managed as outpatients. Severe exacerbations and patients with poor lung function and significant comorbidities are managed exclusively in hospital, the department (standard department or intensive care unit) depends on the patient's condition. Cost of treating exacerbations were set for one event -for mild exacerbation (€ 66.95) and for severe exacerbation (€ 1,060.27) ( Table 4 ).
The average cost for the mild form of COPD was € 26.22, for the moderate form € 30.26, for the severe form € 92.04 and for the very severe form € 267.64 for 1 patient /3 months (Table 2) .
Bronchodilators are the basis of pharmacological treatment of COPD. Modern long acting bronchodilators reduce the number of exacerbations, which accelerate the progression of the disease and are an important cause of mortality in patients with COPD, which accelerate the progression of the disease and are an important cause of mortality in this disease (12, 13) . Inhaled bronchodilators are mainly used in the treatment of COPD, especially used were combinations of bronchodilators with different mechanisms of action proved. The cost of bronchodilator therapy in COPD patients over three months is shown in Table 3 . Expenses for bronchodilators also vary between different types of COPD, for mild COPD it is € 17.44, moderate € 109.54, severe € 219.58 and for very severe COPD it is € 206.15. The costs for drugs is directly proportional to the degree of severity of COPD, the highest costs were recorded in very severe COPD (Table 3 ).
COnCLUSIOn
The cost study is based on the real costs of providers and payers of healthcare and real clinical practice in terms of standard therapies. Only direct costs were included in the cost study. New drugs are expected in the treatment of COPD and the results of the cost study can be used for the purposes of cost-effectiveness pharmaco-economic modeling in this therapeutic area.
In the management of COPD, the most expensive costs are those for hospitalization, outpatient care and symptomatic treatment. The most costly is the management of severe and very severe exacerbations. The big difference was because all severe exacerbations are treated in hospital, which is the most expensive item from all the costs. 
